arrow
M

Montserrat Muñoz-Mateu

azienda ospedaliero universitaria careggi
H指数:50
被引数:9,931

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study

CDK4/6抑制剂剂量模式在老年转移性乳腺癌患者中的分布:一项跨国调查研究

2026-07-010
PRE
Overall Survival with Abemaciclib in Early Breast Cancer

早期乳腺癌中使用Abemaciclib的总体生存率

2025-10-170
OAAI
Ki67 dynamic predicts endocrine sensitivity in estrogen receptor-positive/HER2-negative breast cancer patients undergoing preoperative endocrine therapy

Ki67动态变化可预测接受术前内分泌治疗的雌激素受体阳性/HER2阴性乳腺癌患者的内分泌敏感性。

2025-10-160
OAAI
Preoperative Radiotherapy-Induced Molecular and Immune Modulation in Early-Stage Breast Cancer: Results from the YOUNGSTER Trial

术前放疗诱导的分子和免疫调控在早期乳腺癌中的作用:YOUNGSTER试验的结果

2025-08-050
OA
Retrospective analysis to validate the CTS5 in patients from El Álamo IV registry and GEICAM adjuvant studies

回顾性分析以验证El Álamo IV登记研究和GEICAM辅助研究中患者的CTS5。

2025-04-040
OA
Correlation of the HER2DX Genomic Test withPathologic Features in Early-Stage HER2+BreastCancer
2025-03-010
PRE
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice
2025-02-240
PRE
Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer
2025-01-010
OAAI
Identifying predictors of treatment response and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptorpositive/HER2-negative breast cancer: the NEOENDO translational study
2024-12-011
PRE
Implementing geriatric assessment for dose optimization of CDK4/6 inhibitors in older breast cancer patients
2024-10-211
OAAI
Clinical and molecular characteristics of early-stage triple-negative breast cancer (eTNBC) patients with germline pathogenic variants in homologous recombination repair genes

携带同源重组修复基因胚系致病性变异的早期三阴性乳腺癌(eTNBC)患者的临床与分子特征

2024-09-010
PRE
Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer
2024-07-112
OAAI
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer

新辅助化疗和内分泌治疗在激素受体阳性/HER2-low和HER2-0乳腺癌中引起的临床病理和分子变化

2024-07-013
OAAI
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib plus endocrine therapy in HR+/HER2-metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial
2024-05-020
PRE
Body Mass Index and Treatment Efficacy in advanced Luminal Breast Cancer: Insights from the GEICAM/2013-02 (PEARL) trial
2024-05-020
PRE
Enhancing Informative Outcomes with Liquid Biopsy in a Real-World Population of Patients with Advanced Breast Cancer: Analysis of the SOLTI-1903 HOPE Study
2024-05-020
PRE